Penumbra price target lowered to $290 from $300 at Truist

Truist lowered the firm’s price target on Penumbra to $290 from $300 and keeps a Buy rating on the shares after its Q4 earnigns beat but slightly lower than expected revenue. The midpoint of 2024 revenue outlook was also sub-20% only due to the company’s International businss as key thrombectomy and U.S. engines are forecasted to grow at 22%-25% or more, the analyst tells investors in a research note.